Skip to Content
Merck
CN

Is suppression of apoptosis a new therapeutic target in sepsis?

Anaesthesia and intensive care (2013-03-28)
M Harjai, J Bogra, M Kohli, A B Pant
ABSTRACT

Sepsis remains as a leading cause of death in critically ill patients. Unfortunately, there have been very few successful specific therapeutic agents that can significantly reduce the attributable mortality and morbidity of sepsis. Developing novel therapeutic strategies to improve outcomes of sepsis remains an important focus of ongoing research in the field of critical care medicine. Apoptosis has recently been identified as an important mechanism of cell death and evidence suggests that prevention of cell apoptosis can improve survival in animal models of sepsis and endotoxaemia. In this review article, we summarise the critical role of apoptosis of the immune cells in the pathophysiology of sepsis and propose that blocking cell-signaling pathways leading to apoptosis may present a promising specific therapy for sepsis. Various methods to inhibit apoptosis including the cell surface Fas receptor pathway inhibitors, caspase inhibitors, over-expression of anti-apoptotic genes and small interfering ribonucleic acid therapy are discussed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cytochrome c from Saccharomyces cerevisiae, ≥85% based on Mol. Wt. 12,588 basis
Sigma-Aldrich
ProteoMass Cytochrome c MALDI-MS Standard, vial of 10 nmol, (M+H+) 12,361.96 Da by calculation
Sigma-Aldrich
Cytochrome c from pigeon breast muscle, ≥95% based on Mol. Wt. 12,173 basis
Sigma-Aldrich
Cytochrome c from equine heart, suitable for GFC marker, BioReagent
Sigma-Aldrich
Cytochrome c from equine heart, BioUltra, ≥99% (SDS-PAGE), powder, suitable for mammalian cell culture
Sigma-Aldrich
Cytochrome c from equine heart, ≥95% based on Mol. Wt. 12,384 basis
Sigma-Aldrich
Cytochrome c from equine heart, ≥95% (SDS-PAGE)